cells

Multiple Cancer Types Trials

Multiple Cancer Types
(Domvanalimab + Zimberelimab)

Overview

Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD, and clinical activity of domvanalimab as monotherapy and in combination with zimberelimab in participants with advanced solid malignancies.

Key Eligibility Criteria

  • Pathologically confirmed non-small cell lung cancer, squamous cell carcinoma of the head and neck, renal cell carcinoma, breast cancer, colorectal cancer, melanoma, bladder cancer, ovarian cancer, endometrial cancer, Merkel cell carcinoma, or gastroesophageal cancer that is metastatic, advanced, or recurrent with progression for which no alternative or curative therapy exists or standard therapy is not considered appropriate by the participant and treating physicianEastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
  • No prior malignancy active within the previous year except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix, breast, or prostate cancer

Domvanalimab + Zimberelimab Clinical Trial Locations

clinicaltrials.gov

arrow

Healthcare Professionals: to learn more about Arcus trials, email [email protected]

Patients and Caregivers: Talk to your doctor if you are interested in learning more about Arcus clinical trials.

These molecules and their uses are investigational, have not been proven to be safe, and have not been approved by the U.S. Food and Drug Administration.